RegCell secured $66 million to advance its immune tolerance platform into clinic development. The funding combines a fully subscribed $44 million Series A and a $22 million non-dilutive grant from Japan’s AMED, reflecting strong governmental support for translational immunology efforts. RegCell’s platform centers on regulatory T-cell approaches, aligning with a broader interest in immune tolerance as a route to reduce chronic inflammation and improve outcomes in immune-mediated disease. The dual financing structure signals validation from both private investors and a national health research agency. The next read will be how RegCell uses the capital to progress lead candidates toward IND-enabling work, clinical trial initiation, and proof of mechanism in humans.